MedTrace Logo

Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers

NCT07470125 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-13

No results posted yet for this study

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers

Conditions

  • Healthy Subjects

Interventions

DRUG

YHP2511

Test drug: YHP2511, Comparator: YHP2511A

DRUG

YHP2511A

Test drug: YHP2511, Comparator: YHP2511A

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Seoung Hyun Kang · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-23
Primary Completion
2026-07-11
Completion
2026-07-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07470125 on ClinicalTrials.gov